Intervention Review

You have free access to this content

Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction

  1. Jodie M Dodd1,*,
  2. Anne McLeod2,
  3. Rory C Windrim3,
  4. John Kingdom3

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 24 JUL 2013

Assessed as up-to-date: 24 OCT 2012

DOI: 10.1002/14651858.CD006780.pub3


How to Cite

Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD006780. DOI: 10.1002/14651858.CD006780.pub3.

Author Information

  1. 1

    The University of Adelaide, School of Paediatrics and Reproductive Health, Discipline of Obstetrics and Gynaecology, Adelaide, South Australia, Australia

  2. 2

    University of Toronto, Department of Medicine, Toronto, Canada

  3. 3

    University of Toronto, Department of Obstetrics and Gynaecology, Toronto, Canada

*Jodie M Dodd, School of Paediatrics and Reproductive Health, Discipline of Obstetrics and Gynaecology, The University of Adelaide, Women's and Children's Hospital, 72 King William Road, Adelaide, South Australia, 5006, Australia. jodie.dodd@adelaide.edu.au.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 24 JUL 2013

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 1 Perinatal mortality.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 2 Preterm birth less than 34 weeks' gestation.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 3 Major neurodevelopmental delay at child follow-up.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 4 Pre-eclampsia.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 5 Eclampsia.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 6 Placental abruption.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 7 Antepartum haemorrhage (after 20 weeks requiring hospitalisation).
[Analysis 1.8]
Analysis 1.8. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 8 Mean length of antenatal hospital stay.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 9 Thrombocytopaenia.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 10 Preterm birth less than 37 weeks' gestation.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 11 Infant birthweight less than 2500 grams.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 12 Infant birthweight less than 10th centile for gestational age.
[Analysis 1.13]
Analysis 1.13. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 13 Apgar score less than 7 at 5 minutes age.
[Analysis 1.14]
Analysis 1.14. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 14 NICU admission.
[Analysis 1.15]
Analysis 1.15. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 15 Fetal death.
[Analysis 1.16]
Analysis 1.16. Comparison 1 Heparin (alone or with other medication) versus no treatment, Outcome 16 Neonatal death.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Triazolopyrimidine (Trapidil) versus placebo, Outcome 1 Pre-eclampsia.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Unfractionated heparin versus low molecular weight heparin, Outcome 1 Major neurodevelopmental delay at child follow-up.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Unfractionated heparin versus low molecular weight heparin, Outcome 2 Antepartum haemorrhage (after 20 weeks and requiring hospitalisation).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Unfractionated heparin versus low molecular weight heparin, Outcome 3 Thrombocytopaenia.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Unfractionated heparin versus low molecular weight heparin, Outcome 4 Preterm birth prior to 37 weeks' gestation.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Unfractionated heparin versus low molecular weight heparin, Outcome 5 Infant birthweight less than 10th centile for gestational age.